After the markets close Sept. 21, Aurora Cannabis (NASDAQ: ACB) will release results for its fiscal fourth quarter, which ended June 30. The troubled Canadian pot company’s stock is already down by about 20% year to date — a sharp contrast to the sector benchmark Horizons Marijuana Life Sciences ETF, which is up 5% — and the upcoming report could be pivotal in determining whether the share price gets out of the red for 2021.